FDA Agrees to Amend Special Protocol Assessment for Clinical Trial of AXPAXLI in Wet AMD

BEDFORD, Mass., Jan. 25, 2024 . Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials